WO1991013982A1 - Lactoferrine humaine produite par technique genetique - Google Patents
Lactoferrine humaine produite par technique genetique Download PDFInfo
- Publication number
- WO1991013982A1 WO1991013982A1 PCT/US1991/001335 US9101335W WO9113982A1 WO 1991013982 A1 WO1991013982 A1 WO 1991013982A1 US 9101335 W US9101335 W US 9101335W WO 9113982 A1 WO9113982 A1 WO 9113982A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lactoferrin
- adsorbed
- adsorbent
- column
- human lactoferrin
- Prior art date
Links
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 title claims abstract description 44
- 102000050459 human LTF Human genes 0.000 title claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 48
- 108020004511 Recombinant DNA Proteins 0.000 claims abstract description 11
- 108010063045 Lactoferrin Proteins 0.000 claims description 74
- 235000021242 lactoferrin Nutrition 0.000 claims description 74
- 102000010445 Lactoferrin Human genes 0.000 claims description 73
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 73
- 229940078795 lactoferrin Drugs 0.000 claims description 73
- 239000000463 material Substances 0.000 claims description 41
- 239000003463 adsorbent Substances 0.000 claims description 32
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 24
- 230000008569 process Effects 0.000 claims description 23
- 229910052751 metal Inorganic materials 0.000 claims description 19
- 239000002184 metal Substances 0.000 claims description 19
- 238000011068 loading method Methods 0.000 claims description 18
- 239000000872 buffer Substances 0.000 claims description 17
- 239000002299 complementary DNA Substances 0.000 claims description 16
- 108020004414 DNA Proteins 0.000 claims description 15
- 238000004587 chromatography analysis Methods 0.000 claims description 14
- 239000011573 trace mineral Substances 0.000 claims description 14
- 235000013619 trace mineral Nutrition 0.000 claims description 14
- 229910052742 iron Inorganic materials 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 235000018102 proteins Nutrition 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 9
- 230000000717 retained effect Effects 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 239000005289 controlled pore glass Substances 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 239000013589 supplement Substances 0.000 claims description 6
- 241000235058 Komagataella pastoris Species 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 235000015872 dietary supplement Nutrition 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 239000002609 medium Substances 0.000 claims description 5
- 230000000813 microbial effect Effects 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 230000006872 improvement Effects 0.000 claims description 4
- 229910021645 metal ion Inorganic materials 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- FQYUMYWMJTYZTK-UHFFFAOYSA-N Phenyl glycidyl ether Chemical compound C1OC1COC1=CC=CC=C1 FQYUMYWMJTYZTK-UHFFFAOYSA-N 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 230000000979 retarding effect Effects 0.000 claims description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims description 3
- 235000012239 silicon dioxide Nutrition 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 206010044278 Trace element deficiency Diseases 0.000 claims description 2
- 239000011324 bead Substances 0.000 claims description 2
- 239000000645 desinfectant Substances 0.000 claims 2
- 238000007599 discharging Methods 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 238000000746 purification Methods 0.000 abstract description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 29
- 239000011780 sodium chloride Substances 0.000 description 15
- 239000000499 gel Substances 0.000 description 11
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 9
- 239000007995 HEPES buffer Substances 0.000 description 9
- 238000001042 affinity chromatography Methods 0.000 description 7
- 230000002421 anti-septic effect Effects 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000007990 PIPES buffer Substances 0.000 description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 6
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 6
- 235000011130 ammonium sulphate Nutrition 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 235000020256 human milk Nutrition 0.000 description 5
- 210000004251 human milk Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- YKCWQPZFAFZLBI-UHFFFAOYSA-N cibacron blue Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC=C1S(O)(=O)=O YKCWQPZFAFZLBI-UHFFFAOYSA-N 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000012847 fine chemical Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- -1 nickel Chemical compound 0.000 description 3
- 239000007974 sodium acetate buffer Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000219289 Silene Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000000356 anti-lactoferrin effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000004293 human mammary gland Anatomy 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 235000021056 liquid food Nutrition 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000985 reactive dye Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 1
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241001319148 Pharmacis Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241001080173 Ridens Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229910001447 ferric ion Inorganic materials 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000006151 minimal media Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/50—Isolated enzymes; Isolated proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3481—Organic compounds containing oxygen
- A23L3/3508—Organic compounds containing oxygen containing carboxyl groups
- A23L3/3517—Carboxylic acid esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3526—Organic compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to human lactoferrin.
- human lactoferrin plays an important role in iron transport and utilization in humans.
- a glycoprotein containing about 6% sugar and having a total molecular weight of about 80,000 daltons, human lactoferrin is capable of binding two ferric ions with high affinity.
- the binding constant of iron by lactoferri •n is about 1020 M-1. Although lactoferri•n binds iron tightly, the binding is reversible so that the metal is available upon demand to cells with a need for this essential element.
- Human milk is high in lactoferrin content.
- the high degree of iron absorption from human milk is manifested in a low incidence of iron deficiency anemia among breast fed infants compared to infants fed with cow's milk.
- lactoferrin is a key protein for healthy development of infants.
- production of lactoferrin from human milk poses problems. First, the severely limited amount of human milk, the major source of human lactoferrin, that is available restricts lactoferrin production. Secondly, production of lactoferrin from human milk presents a tremendous risk factor of infectious contamination. That is, it could carry with it a potentially lethal contaminant, such as the AIDS virus, or another undesirable agent.
- the present invention provides human lactoferrin expressed from recombinant DNA.
- the lactoferrin of the present invention is free of naturally occurring contaminants, e.g., proteins and viruses, that would be detrimental to the recipient.
- the present invention also provides a genetically altered organism capable of producing human lactoferrin.
- the present invention provides a method of producing human lactoferrin comprising the steps of (a) isolating DNA encoding human lactoferrin from a cDNA library derived from human breast tissue;
- the present invention also provides a nutritional supplement comprising the trace-element loaded human lactoferrin having at least 35% metal loading and a nutritionally acceptable carrier or diluent.
- the present invention further provides a topical antiseptic comprising an effective amount of lactoferrin having less than 25% metal loading and a pharmaceutically acceptable carrier or diluent.
- Still another aspect of the present invention provides a process for inhibiting food spoilage comprising adding to the food an effective amount of lactoferrin having less than 25% metal loading.
- the present invention also contemplates an improvement in a chromatography process useful in purifying lactoferrin and other proteins comprising the steps of (a) contacting a substance with a first adsorbent to obtain adsorbed and non- adsorbed fractions, (b) eluting the adsorbed fraction with an eluant and (c) contacting the adsorbed fraction with a second adsorbent, wherein the improvement comprises equilibrating the second adsorbent with the eluant followed by contacting the eluate containing the adsorbed fraction with the second adsorbent.
- Fig. 1 is a schematic diagram showing a preferred embodiment of the improved chromatography method of the present invention.
- Fig. 2 is a flow chart showing a preferred embodiment of purifying lactoferrin in accordance with the present invention.
- Lactoferrin is produced according to the present invention using recombinant DNA technology. That is, by using recombinant DNA technology, a polypeptide containing the primary structural conformation of naturally occurring human lactoferrin and possessing its biological properties is produced.
- ⁇ is a cDNA library derived from human RNA and ligated to an appropriate vector according to methods that will be readily apparent to the skilled artisan, e.g., as disclosed in Davis, et al., Basic Methods in Molecular Biology, Elsevier Science Publishing Co., Inc, (1986), the disclosure of which is incorporated herein by reference.
- the RNA is isolated from the human mammary gland and the vector is phage gt 11.
- the cDNA library is screened for positive (DNA carrying the lactoferrin gene) clones using techniques that will be readily apparent to the skilled artisan, such as disclosed in the aforesaid Davis, et al., publication and Rado, et al., Blood, 70, No.
- the cDNA is hybridized to a radiolabeled oligonucleotide probe and the positive clones identified by autoradiography.
- positive clones are identified using lactoferrin antisera, and the antisera- containing clones are recognized using an appropriate development system, such as an avidin/biotin reaction system.
- Large numbers of positive clones are then generated by infecting an appropriate bacterial host, such as E. coli Y 1090, using methods that will be readily apparent to the skilled artisan such as disclosed in the aforesaid Davis, et al., publication. DNA is then isolated from the clones.
- the cDNA encoding lactoferrin is then cut with an appropriate restriction endonuclease such as EcoRI.
- the cut DNA encoding lactoferrin is separated by chromatography.
- the separated cDNA is further sub-cloned into another vector, such as the pGEM-4 plasmid, and the inserted cDNA again excised and separated.
- human lactoferrin is performed using an appropriate expression vector, such as the plasmid pAO804, and an appropriate host organism, such as the yeast Pichia pastoris.
- an appropriate expression vector such as the plasmid pAO804, and an appropriate host organism, such as the yeast Pichia pastoris.
- Other useful hosts include a mammalian cell line such as Chinese hamster ovary (CHO) and expression vectors that will be readily apparent to the skilled artisan. Insertion of the cDNA and expression of the human lactoferrin are carried out according to techniques that will be readily apparent to the skilled artisan, such as disclosed in Rothstein, Methods in Enzymolocry, 101, 202-210 (1983), and Tschopp, et al. , Bio/Technology, 5, 1305-1308 (1987) , the disclosures of which are incorporated herein by reference.
- Purification of the expressed protein according to the present invention is preferably carried out by one of several methods.
- cell-free culture media containing the expressed lactoferrin is passed through a filter that retains material having a molecular weight greater than about 10,000 daltons and then sterilizing the retained protein.
- the material retained by the filter is subjected to a two-step affinity chromatography process.
- the affinity ligand is the reactive dye Cibacron blue F3G-A (color index (C.I.-) 61211, ⁇ max 605(374)nm) disclosed in Bezwoda, et al., Clin. Chim. Acta. , 157, 89-94 (1986) , and Chemical Abstracts Service (CAS) No.
- Cibacron blue F3G-A can be covalently bound to a cross-linked agarose gel by the triazine coupling method as described in Boh e, et al., J. Chromatography, 69. 209- 214 (1972) , the disclosure of which is incorporated herein by reference.
- controlled-pore glass (CPG) or silicic acid is used to further purify the adsorbed material obtained in the first step.
- the improved chromatography process of the present invention is useful in purifying proteins, such as lactoferrin produced in accordance with the present invention.
- crude fermentation broth contained in tank 1 passes to permeable membrane 3, which retains material having a molecular weight greater than 10,000 daltons and passes an ultrafiltrate containing water, salts, and low-molecular-weight proteins.
- the retained material is washed with a buffer and further concentrated.
- the washed material is then applied to chromatography column 5 containing an adsorbent that has been equilibrated with the buffer used to wash the filtered material while valve 7 is open and valve 9 is closed. After non-adsorbed material is discharged through valve 7, valve 7 is closed and valve 9 opened.
- Adsorbed material is then eluted, and the eluate passed directly to the second column 11, containing an adsorbent previously equilibrated with the eluant used to elute the adsorbed material.
- adsorbent column 11 avoids the need for timely and involved medium exchange procedures between the two adsorption steps. Passage of the adsorbed material through column 11 occurs while valve 13 is open and valve 15 is closed. Eluting adsorbed material from column 11 occurs while valve 13 is closed and valve 15 is open, thereby passing eluate from column 11 directly to a filter (not shown) capable of retaining material having a molecular weight of at least 10,000 daltons.
- a filter not shown
- the nutritional supplement of the present invention contains an effective amount of lactoferrin loaded with one or more trace elements, either alone or in combination with one or more nutritionally acceptable carriers or diluents.
- Preferred nutritional supplements include tablets, gelatin capsules, or liquids containing the lactoferrin together with diluents, such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and glycine; binders, such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, and polyvinylpyrrolidone; disintegrants, such as starches, agar, alginic acid or its sodium salt, and effervescent mixtures; as well as absorbents, colorants, flavors and sweeteners.
- diluents such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and glycine
- the trace-element loaded lactoferrin can be added to foods such as baby formula, cereal, and ice cream to enhance the nutritional value of the food.
- the preferred amount of trace element-loaded lactoferrin in the supplement based on the weight of lg of the supplement is 5-50 mg, more preferably 20-30 mg, most preferably 25 mg.
- An effective daily amount of trace element-loaded lactoferrin varies, based on the individual, from about 10-30 mg, preferably 20- 30 mg, more preferably 25 mg.
- the preferred trace element in the supplement is iron, but other trace elements, e.g., zinc and copper, are contemplated within the scope of the present invention.
- Loading lactoferrin with the appropriate trace element is accomplished by simple titration with, e.g. , ferrous ammonium in the presence of bicarbonate, according to methods that will be readily apparent to the skilled artisan. Preferred loading is such that at least 35%, more preferably at least 50%, most preferably at least 70%, of the metal-binding sites are bound to the trace element.
- the lactoferrin contemplated for use in the supplement is preferably of human derivation, more preferably via DNA recombinant means, but other lactoferrins, such as bovine and porcine lactoferrin, are contemplated.
- Lactoferrin can be used as an antiseptic in accordance with the present invention either alone or in the form of a powder, solution, ointment, aerosol spray, or cream to any part of the subject as an aid in the prevention or treatment of microbial infections.
- lactoferrin inhibits the growth microbes, such as bacteria.
- Preferable antiseptics of the present invention include lactoferrin either alone or compounded with carriers such as, saline silica, talcum, stearic acid, its magnesium or calcium salt, polyethyleneglycol, and fatty emulsions and suspensions that will be readily apparent to the skilled artisan.
- Lactoferrin can be applied to food (either solid or liquid) to retard spoilage in accordance with the present invention either alone or compounded with any of the aforesaid nutritionally acceptable carriers or diluents.
- the lactoferrin reduces the iron available for either microbial multiplication or the production of potentially cell-damaging free-radicals that are formed in iron catalyzed reactions from hydrogen peroxide or superoxide.
- the lactoferrin is particularly useful in inhibiting rancidity in meat, which is iron- dependent lipid peroxidation.
- the lactoferrin can be added directly to the liquid or used to coat filters through which the liquid food passes during processing.
- An effective amount of the lactoferrin for retarding spoilage varies depending on the type and amount of food contemplated.
- the amount of lactoferrin applied to food in accordance with the present invention varies from 0.1-1 mg/ml of food with which it is mixed, or based on the surface area of the filter or solid food to which it is applied from 0.1-1 mg/6 cm 2 .
- the preferred amount of lactoferrin compounded with a carrier in a food additive for retarding spoilage varies based on 1 ml of the carrier from 0.1-2 mg, preferably 0.2-2 mg.
- the same amounts of metal loading preferred for the antiseptic of the present invention are preferred for the food-spoilage retardant.
- the antiseptic, dietary supplement, and food-spoilage retardant of the present invention can be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances.
- adjuvants such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating osmotic pressure and/or buffers.
- they may also contain other therapeutically valuable substances.
- Said compositions are prepared according to conventional mixing, granulating, and coating methods. To more clearly describe the present invention, the following non-limiting examples are provided. In the examples all parts and percentages are by weight unless indicated otherwise.
- human lactoferrin is obtained from a genetically altered organism. Using breast tissue excised during the mastectomy of a woman during the eighth month of pregnancy, a human mammary gland genomic . library (cDNA ligated to ⁇ gt 11) is prepared according to Gubler, et al.,
- the library is transferred onto agar plates containing a high density of E. coli Y 1090 (available from Clontech, California) (5 x 10 4 plaques per 90 mm plate or 1.4 x 10 5 plaques per 150 mm plate. The plates are allowed to stand for 3.5 hours at 42°C to obtain a lytic growth of the phage.
- E. coli Y 1090 available from Clontech, California
- Positive clones i.e., containing the cDNA are identified on the membranes using rabbit antibody to natural human lactoferrin purified in accordance with Example 8 herein.
- Nitrocellulose filters are removed from the plates after plaque transferral, and the coated with the antibody purified in accordance with Example 8, which hybridizes with positive plaques.
- positive plaques are developed by first applying an anti-rabbit IgG conjugated with biotin (available from Sigma Chemical Co., St. Louis, MO) , and then, following removal of excess biotin conjugate, applying avidin conjugated with horse radish peroxidase (available from Sigma Chemical Co., St Louis, MO) .
- the positive plaques are identified in the reaction catalyzed by horse radish peroxidase using as an enzyme substrate 4-chloro-l-Naphtol.
- the positive plaques are then used to infect E. Coli Y 1090 to produce large amounts of phage in accordance with procedures set forth in Davis, et. al., supra.
- the resulting bacteriophage is purified using 10% polyethylene glycol and DNA is isolated from the phage according to the procedures disclosed in Kislow, N.A.R. , 14.
- the cDNA insert encoding lactoferrin is sub-cloned as follows: the cDNA insert is cut out from the phage DNA using EcoRI and purified using a high resolution ion-exchange chromatography column (Gen-PakTM Fax available from Millipore Corporation, Waters Chromatography Division, Milford, MA) . The thus purified cDNA insert is ligated using T4 DNA ligase into plasmid pGEM-4 (available from Promega, Madison, WI, and described in Yanish-Perron et al.
- E. coli JM109 available from Promega, Madison, WI, and described in Hanahan, J. Mil. Biol. , 166, 557 (1983)). The bacteria are transferred to agar plates containing ampicillin and the positive colonies grown. The plasmid is then isolated and the cDNA insert is cut from the plasmid using EcoRI and purified by ion-exchange chromatography as described above.
- the cDNA insert is then ligated into the Pichia pastoris expression vector pAO804 (using the P. pastoris GTS 115 strain) so as to be flanked by the 5' and 3' regulatory sequences of the methanol-induced alcohol oxidase gene (AOX1) of P. pastoris in accordance with the procedures described in Sreekrishna, et al., Biochemistry, 28, 4117-4125 (1989), and Rothstein, Methods in Enzvmology, 101, 202-210 (1983) , the disclosures of which are incorporated herein by reference.
- the thus modified vector is then grown in minimal media as described in Creeg, et al., Mol. Cell.
- EXAMPLE 2 human lactoferrin is purified in accordance with the present invention.
- One liter of the supernatant from Example 1 is adjusted to about 4°C and filtered under pressure through a polysulfone ultrafiltration membrane having a pH operating range of 1-14 on a polypropylene mesh support (Pellicon Cassette filter System assembled with Procon pump and PTGC membrane available from Millipore) to retain proteins in excess of about 10,000 molecular weight.
- Pressure with simultaneous circulation is applied until 900 ml of ultrafiltrate is collected.
- a flow rate of about 100 ml per minute is maintained during the filtration process.
- the final material retained is sterilized (0.22 ⁇ m Gelman filter).
- EXAMPLE 3 human lactoferrin is purified in accordance with a preferred embodiment of the present invention using affinity chromatography in which the affinity ligand is the reactive dye Cibacron blue F3G-A.
- the sterilized material obtained in Example 2 is adjusted to a pH of 7.5 and a final concentration of sodium chloride of 0.5 M.
- EXAMPLE 5 human lactoferrin is purified in accordance with a preferred embodiment of the present invention using immobilized metal ion affinity chromatography (IMAC) .
- IMAC immobilized metal ion affinity chromatography
- An imminodiacetic acid-epoxy activated gel (available from Pharmacia Fine Chemicals, Upsala, Sweden, under the name Chelating SepharoseTM 6B) is washed with water and equilibrated with 0.1 M sodium acetate buffer (pH 4.0) containing 1 M sodium chloride.
- the gel is then packed into a chromatographic column (1.2 cm x 10 cm) and saturated with 4 bed volumes of the same sodium acetate buffer further containing 5 mg/ml of nickel chloride.
- Excess metal is washed from the column with the sodium acetate buffer, and the gel is equilibrated with 20 mM HEPES buffer (pH 7.0) containing 1 M sodium chloride and 2 mM imidazol.
- Example 4 The product of Example 4 is mixed with HEPES, sodium chloride, and imidazol to obtain a pH of 7.0, 20 mM HEPES, 1 M sodium chloride, and 2 mM imidazol.
- the mixture is applied onto the column at a flow rate of about 1 ml/min followed by washing the gel with 2 bed volumes of 20 mM HEPES buffer (pH 7.0) containing 1 M sodium chloride and 2 mM imidazol.
- the non-adsorbed fraction is discarded, and the adsorbed fraction containing lactoferrin is eluted using 2 bed volumes of 20 mM HEPES buffer (pH 7.0) containing 1 M sodium chloride and 20 mM imidazol.
- EXAMPLE 6 human lactoferrin is purified in accordance with a preferred embodiment of the present invention using T-Gel affinity chromatography.
- T-gel adsorbent is prepared according to Porath, et al., Methods in Enzvmology, 44. 19- 45 (1976) , the disclosure of which is incorporated herein by reference, and packed into a column (1.2 cm x 10 cm).
- the final product of Example 4 is adjusted to a pH of 7.5 and a final concentration as follows: 50 mM PIPES buffer (piperazine-N,N*-bis[2-ethanesulfonic acid] and 1,4- piperazinediethanesulfonic acid] buffer and 0.7 M ammonium sulfate.
- the adjusted material is applied on the column that has been previously equilibrated to 50 mM PIPES buffer (pH 7.5) containing 0.7 M ammonium sulfate with a flow rate of about lml/min.
- the non-adsorbed fraction containing lactoferrin is adjusted to a concentration of.0.1 M ammonium sulfate and then applied to an identical T-gel column previously equilibrated to 50 mM PIPES buffer (pH 7.5) containing 1.0 M ammonium sulfate.
- the column is then washed with 7-8 bed volumes of 50 mM PIPES buffer (pH 7.5) containing 1.0 M ammonium sulfate, with lactoferrin being present in the non-adsorbed fraction.
- Sepharose TM CL-4B avai•lable from Pharmaci•a Fi•ne Chemi•cals, Upsala, Sweden
- the gel is packed into a column and equilibrated to 50 mM PIPES buffer (pH 7.0) containing 1 M ammonium sulfate.
- the product of Example 4 is adjusted to the equilibrating buffer and applied onto the column at a flow rate of 1 ml/min.
- the non-adsorbed fraction is discarded and the adsorbed fraction containing lactoferrin is eluted using 2 bed volumes of 50 mM PIPES buffer (pH 7.0) .
- anti-lactoferrin serum is purified by affinity chromatography for use in accordance with a preferred embodiment of the present invention as described in Example 1 herein.
- the adsorbent substrate for affinity chromatography is prepared by cyanogen bromide activation as described by Axen et al., Nature, 214, 1302-1304 (1967) .
- the substrate available from Pharmacia Fine Chemicals, Upsala,
- the gel is then washed with coupling buffer, followed by 0.1 M acetate buffer (pH 4.0) containing 0.5 M sodium chloride, followed again by coupling buffer to form the adsorbent.
- the adsorbent is packed into a column and washed with 20 mM phosphate buffer (pH 7.4) containing 0.5 M sodium chloride.
- Anti-lactoferrin serum obtained from an inoculated rabbit (available from Sigma Chemical Co. , St Louis, MO) is passed through the column at a flow rate of 1 ml/min and the non-adsorbed material discarded.
- Adsorbed material containing the purified protein is eluted with 2 bed volumes of 0.2 M glycine buffer (pH 2.0) containing 0.5 M of sodium chloride. The eluate is neutralized with 0.1N NaOH to obtain pH 7.5 and then steri •li•zed (0.22 ⁇ m GelmanTM fi•lter) and frozen at -20°C.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Pest Control & Pesticides (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Virology (AREA)
- Agronomy & Crop Science (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
On décrit une lactoferrine humaine extraite de l'ADN recombinant, le procédé de fabrication et de purification de celle-ci ainsi que son utilisation.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48918690A | 1990-03-08 | 1990-03-08 | |
US489,186 | 1990-03-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991013982A1 true WO1991013982A1 (fr) | 1991-09-19 |
Family
ID=23942756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1991/001335 WO1991013982A1 (fr) | 1990-03-08 | 1991-02-28 | Lactoferrine humaine produite par technique genetique |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU7453391A (fr) |
WO (1) | WO1991013982A1 (fr) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0603187A1 (fr) * | 1991-05-31 | 1994-06-29 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Lactoferrine humaine |
EP0644899A1 (fr) * | 1992-04-24 | 1995-03-29 | Baylor College Of Medicine | Production de lactoferrine humaine de recombinaison |
WO1995030339A1 (fr) * | 1994-05-05 | 1995-11-16 | Ferrodynamics, Inc. | Clonage, expression et utilisations de la lactoferrine humaine |
WO1996014413A1 (fr) * | 1994-11-02 | 1996-05-17 | Agennix, Inc. | Expression de lactoferrines et de fragments polypeptidiques de lactoferrines recombines traites, a partir d'un produit de fusion, dans aspergillus |
US5571691A (en) * | 1989-05-05 | 1996-11-05 | Baylor College Of Medicine | Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms |
WO1997045136A1 (fr) * | 1996-05-31 | 1997-12-04 | Baylor College Of Medicine | Variantes de lactoferrine et leurs emplois |
WO2000004132A1 (fr) * | 1998-07-15 | 2000-01-27 | Samyang Genex Corporation | Production massive de lactoferrine a partir de levure et micro-organisme utile ainsi obtenu |
WO2000072874A1 (fr) * | 1999-05-28 | 2000-12-07 | Naidu A Satyanarayan | Agents antimicrobiens de lactoferrine (im-lf) immobilisee et utilisations associees |
US6228614B1 (en) | 1989-05-05 | 2001-05-08 | Baylor College Of Medicine | Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms |
US6423509B1 (en) | 1998-07-15 | 2002-07-23 | Samyang Genex Corporation | Pichia pastoris strain for producing lactoferrin and methods of use |
US7034126B2 (en) * | 2003-05-14 | 2006-04-25 | Agennix, Inc. | Lactoferrin in the treatment of diabetes mellitus |
US7125963B2 (en) | 2004-03-03 | 2006-10-24 | En N Tech Inc | Treatments for contaminant reduction in lactoferrin preparations and lactoferrin containing compositions |
US7183381B2 (en) | 2004-10-26 | 2007-02-27 | Agennix, Inc. | Composition of lactoferrin related peptides and uses thereof |
WO2023004153A1 (fr) * | 2021-07-23 | 2023-01-26 | Clara Foods Co. | Compositions de protéines purifiées et leurs procédés de production |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4436658A (en) * | 1981-05-15 | 1984-03-13 | Societe Nationale Elf Aquitaine | Process of extraction of lactoferrine and immunoglobulins of milk |
-
1991
- 1991-02-28 AU AU74533/91A patent/AU7453391A/en not_active Abandoned
- 1991-02-28 WO PCT/US1991/001335 patent/WO1991013982A1/fr unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4436658A (en) * | 1981-05-15 | 1984-03-13 | Societe Nationale Elf Aquitaine | Process of extraction of lactoferrine and immunoglobulins of milk |
Non-Patent Citations (5)
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6228614B1 (en) | 1989-05-05 | 2001-05-08 | Baylor College Of Medicine | Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms |
US5571697A (en) * | 1989-05-05 | 1996-11-05 | Baylor College Of Medicine Texas Medical Center | Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus |
US5571691A (en) * | 1989-05-05 | 1996-11-05 | Baylor College Of Medicine | Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms |
US6080559A (en) * | 1989-05-05 | 2000-06-27 | Agennix, Inc. | Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus |
US5955316A (en) * | 1989-05-05 | 1999-09-21 | Agennix, Inc. | Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in aspergillus |
EP0603187A4 (en) * | 1991-05-31 | 1995-08-30 | Us Health | Human lactoferrin. |
US5948613A (en) * | 1991-05-31 | 1999-09-07 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of screening for risk of cancer using human lactoferrin DNA probe or primer |
EP0603187A1 (fr) * | 1991-05-31 | 1994-06-29 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Lactoferrine humaine |
EP0644899A1 (fr) * | 1992-04-24 | 1995-03-29 | Baylor College Of Medicine | Production de lactoferrine humaine de recombinaison |
EP0644899A4 (fr) * | 1992-04-24 | 1996-06-26 | Baylor College Medicine | Production de lactoferrine humaine de recombinaison. |
US5571896A (en) * | 1992-04-24 | 1996-11-05 | Baylor College Of Medicine | Production of recombinant human lactoferrin |
WO1995030339A1 (fr) * | 1994-05-05 | 1995-11-16 | Ferrodynamics, Inc. | Clonage, expression et utilisations de la lactoferrine humaine |
WO1996014413A1 (fr) * | 1994-11-02 | 1996-05-17 | Agennix, Inc. | Expression de lactoferrines et de fragments polypeptidiques de lactoferrines recombines traites, a partir d'un produit de fusion, dans aspergillus |
US6111081A (en) * | 1996-05-31 | 2000-08-29 | Baylor College Of Medicine | Lactoferrin variants and uses thereof |
WO1997045136A1 (fr) * | 1996-05-31 | 1997-12-04 | Baylor College Of Medicine | Variantes de lactoferrine et leurs emplois |
US6423509B1 (en) | 1998-07-15 | 2002-07-23 | Samyang Genex Corporation | Pichia pastoris strain for producing lactoferrin and methods of use |
WO2000004132A1 (fr) * | 1998-07-15 | 2000-01-27 | Samyang Genex Corporation | Production massive de lactoferrine a partir de levure et micro-organisme utile ainsi obtenu |
US7375080B1 (en) * | 1999-05-28 | 2008-05-20 | Naidu A Satyanarayan | Immobilized lactoferrin (Im-LF) antimicrobial agents and uses thereof |
WO2000072874A1 (fr) * | 1999-05-28 | 2000-12-07 | Naidu A Satyanarayan | Agents antimicrobiens de lactoferrine (im-lf) immobilisee et utilisations associees |
WO2000072690A3 (fr) * | 1999-05-28 | 2001-05-10 | A Satyanarayan Naidu | Agents antimicrobiens de lactoferrine immobilisee (im-lf) et utilisations associees |
AU776657B2 (en) * | 1999-05-28 | 2004-09-16 | A. Satyanarayan Naidu | Immobilized lactoferrin (Im-LF) antimicrobial agents and uses thereof |
US7034126B2 (en) * | 2003-05-14 | 2006-04-25 | Agennix, Inc. | Lactoferrin in the treatment of diabetes mellitus |
US7326775B2 (en) | 2004-03-03 | 2008-02-05 | En-N-Tech, Inc. | Treatments for contaminant reduction in lactoferrin preparations and lactoferrin-containing compositions |
US7125963B2 (en) | 2004-03-03 | 2006-10-24 | En N Tech Inc | Treatments for contaminant reduction in lactoferrin preparations and lactoferrin containing compositions |
US7183381B2 (en) | 2004-10-26 | 2007-02-27 | Agennix, Inc. | Composition of lactoferrin related peptides and uses thereof |
US7420033B2 (en) | 2004-10-26 | 2008-09-02 | Agennix, Inc. | Composition of lactoferrin related peptides and uses thereof |
WO2023004153A1 (fr) * | 2021-07-23 | 2023-01-26 | Clara Foods Co. | Compositions de protéines purifiées et leurs procédés de production |
US11718644B2 (en) | 2021-07-23 | 2023-08-08 | Clara Foods Co. | Purified protein compositions and methods of production |
Also Published As
Publication number | Publication date |
---|---|
AU7453391A (en) | 1991-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6455687B1 (en) | Human lactoferrin | |
WO1991013982A1 (fr) | Lactoferrine humaine produite par technique genetique | |
EP0556083B1 (fr) | Procédé pour la production de substances biologiquement actives à partir du lait et de matières premières apparentées | |
EP0231236B1 (fr) | Purification de l'hemoglobine et hemoglobine modifiee par chromatographie par affinite | |
EP0620709B1 (fr) | Procede d'isolation de lactoferrine et de lactoperoxydase a partir du lait et des produits laitiers | |
US5840851A (en) | Purification of hemoglobin | |
US4406830A (en) | Regulatory glycoprotein for immune response and the use thereof in the production of T-cell growth factor | |
AU2940297A (en) | Purification of biologically active peptides from milk | |
JPH0454198A (ja) | ヒト血清アルブミンの着色抑制方法 | |
JP3438735B2 (ja) | 上清iv、特にiv−4またはコーンフラクションvまたはそれと類似の上清または画分からヒトアルブミンを単離する方法 | |
CA2059979C (fr) | Complexe contenant le facteur de coagulation ix | |
WO2013068538A1 (fr) | Procédé de purification de la téicoplanine | |
EP1717311B1 (fr) | Procede pour produire de la lactoperoxydase | |
WO1995030339A1 (fr) | Clonage, expression et utilisations de la lactoferrine humaine | |
KR100381982B1 (ko) | 사람혈청알부민의탈색방법 | |
US4681844A (en) | Process for producing an Interleukin-1 preparation | |
US4661447A (en) | Regulatory glycoprotein for immune response and the use there of in the production of T-cell growth factor | |
US4526782A (en) | Process for recovering interferon | |
KR100372931B1 (ko) | 팽창층 겔 흡착-이온교환 크로마토그래피법을 이용한 박테리오신의 분리 정제 방법 | |
CA2073043C (fr) | Methode de purification de la cuivre/zinc (cu-zn) superoxyde dismutase obtenue a partir de recombinants de bacteries ou de cellules d'eucaryotes | |
US4808533A (en) | Method of preventing T-cell blastogenesis | |
FI71576B (fi) | Foerfarande foer desinficiering av immobiliserade enzymerna | |
KR930008097B1 (ko) | 콜로니 형성 자극 인자의 정제방법 | |
AU715902B2 (en) | Purification of hemoglobin | |
Kessler et al. | Applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |